Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

Research and Innovation Action · Running

OCTOPOD-Ph2a A Novel Phase-2a Clinical Trial for a Next-Generation Oncolytic Immunotherapy Targeting Platinum-Resistant Ovarian Cancer

Coordinator
Theolytics Ltd, United Kingdom
Runs
1 June 2026 to 31 May 2029
Status
Running
EU funding
€8.0m
Total cost
€8.0m
Partners
5 organisations in 3 countries
Type
Research and Innovation Action
Grant agreement
101289129

What the project is doing

In the project's own words, from its summary on CORDIS.

Annually 87,894 EU citizens are diagnosed with ovarian cancer (OC), with >75% at an advanced stage and poor long-term outcomes (<25% 5-year survival). Standard-of-care first-line treatments combine cytoreductive surgery, platinum-based chemotherapies, and paclitaxel. Although initially effective, most patients relapse (>70% within 3-years) and become resistant to treatment. There are no effective treatments for platinum-resistant OC (PROC) and patients have a life expectancy of <12-months.

Therapeutic challenges result from the heterogeneous and immune-suppressed nature of the tumour microenvironment, and high volume of cancer-associated fibroblasts (CAFs), that create barriers to treatment and promote tumour survival mechanisms. THEO-260 is a next-generation oncolytic virus demonstrating:- world-first dual efficacy, targeting both patient CAF- and cancer- cells- high tumour selectivity (low toxicity)- strong TME modulation (immune cell infiltration) and adaptive immune responses- high systemic activity (intravenous delivery via standard-of-care practices and treatment of metastatic tumours)Currently in Phase-1 trials, THEO-260 is expected to deliver a game-changer in PROC treatment, tripling patient survival, improving quality-of-life, and doubling 5-year survival rates for advanced stage disease.

The project assembles a world class consortium, comprising one of Europe’s leading SME OV Biotechs and 4 centres of excellence in the fields of gynaecological cancer, immunotherapies, and translational research. Our goals are to:- complete a 20-patient multi-centre, open label Phase-2a trial to assess preliminary efficacy,- undertake comprehensive translational research to assess THEO-260's pharmacokinetic, pharmacodynamic, and immune behaviour, and- leverage our partnership and knowhow to consolidate OV clinical development capabilities and best-practice within Europe (increasing OV trial capacity and accelerating development).

Topics

Who is involved

OrganisationCityCountryRole
Theolytics LtdOxfordUnited KingdomCoordinator
University Health NetworkTorontoCanadaParticipant
Institut Catala D'oncologiaHospitalet de LlobregatSpainParticipant
Universidad De NavarraPamplonaSpainParticipant
Institute of Cancer Research: the Royal Cancer Hospital LbgLondonUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI